View in EDS HTML Full Text PDF Full Text

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.
Authors: Gomez-Mancilla B; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Dürsteler KM; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland., Vogel M; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Psychiatric Services of Thurgovia, Psychiatric Hospital Münsterlingen, Münsterlingen, Switzerland., Herdener M; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland., Torrens M; Addiction Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, University of Vic-Central de Catalunya, and Red de investigación en Atención Primaria de Adicciones (RIAPAd), Barcelona, Spain., Gálvez BP; Department of Clinical Medicine, Universidad Miguel Hernández, Edificio Muhammad Al-Shafra, Campus de San Juan, Alicante, Spain.; Addictive Behaviors Unit, Hospital Universitario San Juan, Alicante, Spain., Gual A; Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain., Corral RM; University of Buenos Aires, Buenos Aires, Argentina., Kuper EI; Centro Neurobiológico y de Stress Traumático-Biopsychomedical Research Group, Buenos Aires, Argentina., Mosca DL; Instituto Nacional Psicopatologia, Buenos Aires, Argentina., Dumitras S; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Pezous N; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Berkheimer M; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Walker E; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Gasparini F; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Cha JH; Novartis Biomedical Research, Cambridge, MA, USA., Dolmetsch R; Novartis Biomedical Research, Cambridge, MA, USA.
Source: Science translational medicine [Sci Transl Med] 2025 Apr 02; Vol. 17 (792), pp. eadi4505. Date of Electronic Publication: 2025 Apr 02.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40173260
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gomez-Mancilla+B%22">Gomez-Mancilla B</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dürsteler+KM%22">Dürsteler KM</searchLink>; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Vogel+M%22">Vogel M</searchLink>; Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland.; Psychiatric Services of Thurgovia, Psychiatric Hospital Münsterlingen, Münsterlingen, Switzerland.<br /><searchLink fieldCode="AU" term="%22Herdener+M%22">Herdener M</searchLink>; Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Torrens+M%22">Torrens M</searchLink>; Addiction Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, University of Vic-Central de Catalunya, and Red de investigación en Atención Primaria de Adicciones (RIAPAd), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gálvez+BP%22">Gálvez BP</searchLink>; Department of Clinical Medicine, Universidad Miguel Hernández, Edificio Muhammad Al-Shafra, Campus de San Juan, Alicante, Spain.; Addictive Behaviors Unit, Hospital Universitario San Juan, Alicante, Spain.<br /><searchLink fieldCode="AU" term="%22Gual+A%22">Gual A</searchLink>; Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Corral+RM%22">Corral RM</searchLink>; University of Buenos Aires, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Kuper+EI%22">Kuper EI</searchLink>; Centro Neurobiológico y de Stress Traumático-Biopsychomedical Research Group, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Mosca+DL%22">Mosca DL</searchLink>; Instituto Nacional Psicopatologia, Buenos Aires, Argentina.<br /><searchLink fieldCode="AU" term="%22Dumitras+S%22">Dumitras S</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Pezous+N%22">Pezous N</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Berkheimer+M%22">Berkheimer M</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Walker+E%22">Walker E</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Gasparini+F%22">Gasparini F</searchLink>; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Cha+JH%22">Cha JH</searchLink>; Novartis Biomedical Research, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dolmetsch+R%22">Dolmetsch R</searchLink>; Novartis Biomedical Research, Cambridge, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101505086%22">Science translational medicine</searchLink> [Sci Transl Med] 2025 Apr 02; Vol. 17 (792), pp. eadi4505. <i>Date of Electronic Publication: </i>2025 Apr 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+the+Advancement+of+Science%22">American Association for the Advancement of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101505086 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1946-6242 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219466234%22">19466234 </searchLink><i>NLM ISO Abbreviation: </i>Sci Transl Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40173260
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1126/scitranslmed.adi4505
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: eadi4505
    Titles:
      – TitleFull: Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gomez-Mancilla B
      – PersonEntity:
          Name:
            NameFull: Dürsteler KM
      – PersonEntity:
          Name:
            NameFull: Vogel M
      – PersonEntity:
          Name:
            NameFull: Herdener M
      – PersonEntity:
          Name:
            NameFull: Torrens M
      – PersonEntity:
          Name:
            NameFull: Gálvez BP
      – PersonEntity:
          Name:
            NameFull: Gual A
      – PersonEntity:
          Name:
            NameFull: Corral RM
      – PersonEntity:
          Name:
            NameFull: Kuper EI
      – PersonEntity:
          Name:
            NameFull: Mosca DL
      – PersonEntity:
          Name:
            NameFull: Dumitras S
      – PersonEntity:
          Name:
            NameFull: Pezous N
      – PersonEntity:
          Name:
            NameFull: Berkheimer M
      – PersonEntity:
          Name:
            NameFull: Walker E
      – PersonEntity:
          Name:
            NameFull: Gasparini F
      – PersonEntity:
          Name:
            NameFull: Cha JH
      – PersonEntity:
          Name:
            NameFull: Dolmetsch R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 04
              Text: 2025 Apr 02
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1946-6242
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 792
          Titles:
            – TitleFull: Science translational medicine
              Type: main
ResultId 1